Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.

Authors:
Scott G Soltys Clara Y H Choi Willard E Fee Harlan A Pinto Quynh-Thu Le

Int J Radiat Oncol Biol Phys 2012 Jul 2;83(3):994-9. Epub 2011 Dec 2.

Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305-5847, USA.

Purpose: To assess the role of a planned neck dissection (PND) after sequential chemoradiotherapy for patients with head-and-neck cancer with N2-N3 nodal disease.

Methods And Materials: We reviewed 90 patients with N2-N3 head-and-neck squamous cell carcinoma treated between 1991 and 2001 on two sequential chemoradiotherapy protocols. All patients received induction and concurrent chemotherapy with cisplatin and 5-fluorocuracil, with or without tirapazamine. Patients with less than a clinical complete response (cCR) in the neck proceeded to a PND after chemoradiation. The primary endpoint was nodal response. Clinical outcomes and patterns of failure were analyzed.

Results: The median follow-up durations for living and all patients were 8.3 years (range, 1.5-16.3 year) and 5.4 years (range, 0.6-16.3 years), respectively. Of the 48 patients with nodal cCR whose necks were observed, 5 patients had neck failures as a component of their recurrence [neck and primary (n = 2); neck, primary, and distant (n = 1); neck only (n = 1); neck and distant (n = 1)]. Therefore, PND may have benefited only 2 patients (4%) [neck only failure (n = 1); neck and distant failure (n = 1)]. The pathologic complete response (pCR) rate for those with a clinical partial response (cPR) undergoing PND (n = 30) was 53%. The 5-year neck control rates after cCR, cPR→pCR, and cPR→pPR were 90%, 93%, and 78%, respectively (p = 0.36). The 5-year disease-free survival rates for the cCR, cPR→pCR, and cPR→pPR groups were 53%, 75%, and 42%, respectively (p = 0.04).

Conclusion: In our series, patients with N2-N3 neck disease achieving a cCR in the neck, PND would have benefited only 4% and, therefore, is not recommended. Patients with a cPR should be treated with PND. Residual tumor in the PND specimens was associated with poor outcomes; therefore, aggressive therapy is recommended. Studies using novel imaging modalities are needed to better assess treatment response.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ijrobp.2011.07.042DOI Listing
July 2012

Publication Analysis

Top Keywords

sequential chemoradiotherapy
12
patients
11
neck
10
pnd benefited
8
ccr neck
8
ccr cpr→pcr
8
rates ccr
8
neck distant
8
patients n2-n3
8
complete response
8
years range
8
cpr→pcr cpr→ppr
8
neck dissection
8
head-and-neck cancer
8
planned neck
8
pnd
7
ccr
5
response
5
failures component
4
observed patients
4

Keyword Occurance

Similar Publications

Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.

Authors:
Chen Li Xin Wang Lan Wang Junqiang Chen Wencheng Zhang Qingsong Pang Yidian Zhao Xinchen Sun Kaixian Zhang Gaofeng Li Ling Li Xueying Qiao Miaoling Liu Yadi Wang Lei Deng Wenqing Wang Nan Bi Tao Zhang Wei Deng Wenjie Ni Xiao Chang Weiming Han Zongmei Zhou Jun Liang Qinfu Feng Lvhua Wang Dongfu Chen Jima Lv Shuchai Zhu Chun Han Zefen Xiao

Acta Oncol 2021 Apr 1:1-8. Epub 2021 Apr 1.

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Purpose: To determine the survival and prognostic factors of esophageal squamous cell carcinoma (ESCC) patients undergoing radical (chemo)radiotherapy in the era of three-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) in China.

Material And Methods: The Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG) conducted the first nationwide survey of nine institutions. Detailed information was accumulated on 5185 patients with ESCC who received definitive 3DCRT/IMRT between 2002 and 2018. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.

Authors:
Jelle Evers Katrien de Jaeger Lizza E L Hendriks Maurice van der Sangen Chris Terhaard Sabine Siesling Dirk De Ruysscher Henk Struikmans Mieke J Aarts

Lung Cancer 2021 Mar 20;155:103-113. Epub 2021 Mar 20.

Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands. Electronic address:

Introduction: This Dutch population-based study describes nationwide treatment patterns and its variations for stage I-III non-small cell lung cancer (NSCLC).

Materials And Methods: Patients diagnosed with clinical stage I-III NSCLC in the period 2008-2018 were selected from the Netherlands Cancer Registry. Treatment trends were studied over time and age groups. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection.

Authors:
Yaowen Zhang Junhui Gao Anping Zheng Haijun Yang Jian Li Shouxin Wu Jiangman Zhao Peng Meng Fuyou Zhou

Transl Oncol 2021 Mar 18;14(6):101066. Epub 2021 Mar 18.

Department of Radiation Oncology, Anyang Cancer Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang 455000, China. Electronic address:

Early recurrence after surgery could affect cancerous patients' prognosis, but the definition of early recurrence and its risk factors for esophageal squamous cell carcinoma (ESCC) patients are still unclear. This study analyzed the clinical data of 468 post-surgery recurrent ESCC patients retrospectively. A minimum p-value approach was used to evaluate the optimal cut-off value of recurrence free survival (RFS) to define early recurrence. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.

Authors:
Wei Xiao Mei Hong

Medicine (Baltimore) 2021 Mar;100(11):e21455

Nanjing Chest Hospital, Nanjing, Jiangsu Province, China.

Background: Chemotherapy in combination with thoracic radiotherapy yields significant results in patients with advanced non-small-cell lung cancer (NSCLC) compared with thoracic radiotherapy alone. However, whether concurrent or sequential delivery of chemotherapy combined with thoracic radiotherapy is optimal remains unclear. Herein, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of concurrent vs sequential chemoradiotherapy in patients with NSCLC. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.

Authors:
Frederick Mantel Elena Müller Philip Kleine Marcus Zimmermann Florian Exner Anne Richter Stefan Weick Serge Ströhle Bülent Polat Stefan Höcht Michael Flentje

Strahlenther Onkol 2021 Mar 16. Epub 2021 Mar 16.

Department of Radiation Oncology, University of Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany.

Purpose: Integrating moderate hypofractionation to the macroscopic tumor with elective nodal irradiation while sparing the organs at risk (OAR) in chemoradiotherapy of locally advanced non-small-cell lung cancer.

Methods: From 2010-2018, treatment, patient and tumor characteristics of 138 patients from two radiation therapy centers were assessed. Chemoradiotherapy by intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost (SIB) to the primary tumor and macroscopic lymph node metastases was used. Read More

View Article and Full-Text PDF
March 2021
Similar Publications